m<sup>6</sup>A transferase METTL3‐induced lncRNA ABHD11‐AS1 promotes the Warburg effect of non‐small‐cell lung cancer

Xue, Lei; Li, Jun; Lin, Yuan; Liu, Degang; Yang, Qiang; Jian, Jinting; Peng, Jiangzhou

doi:10.1002/jcp.30023

Cited by 133 publications

(116 citation statements)

References 30 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…11 Additionally, m 6 A methyltransferase-like 3 (METTL3)-induced lncRNA ABHD11-AS1 is upregulated in NSCLC, and its ectopic expression is closely related to the poor prognosis of patients with NSCLC. 12 Recently, several bioinformatics studies have shown that the dysregulation of m 6 A regulators is involved in LUAD. 13,14 The specific role of m 6 A regulators in lncRNAs remains unclear; therefore, understanding the mechanism of m 6 A-related lncRNAs in the development of LUAD may be useful for prognostic targets.…”

Section: Introductionmentioning

confidence: 99%

m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

Huang

et al. 2021

Molecular Therapy - Nucleic Acids

165

141

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide. However, the survival rate of LUAD patients remains low. N6-methyladenosine (m 6 A) and long noncoding RNAs (lncRNAs) play vital roles in the prognostic value and the immunotherapeutic response of LUAD. Thus, discerning lncRNAs associated with m 6 A in LUAD patients is critical. In this study, m 6 A-related lncRNAs were analyzed and obtained by coexpression. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were conducted to construct an m 6 Arelated lncRNA model. Kaplan-Meier analysis, principalcomponent analysis (PCA), functional enrichment annotation, and nomogram were used to analyze the risk model. Finally, the potential immunotherapeutic signatures and drug sensitivity prediction targeting this model were also discussed. The risk model comprising 12 m 6 A-related lncRNAs was identified as an independent predictor of prognoses. By regrouping the patients with this model, we can distinguish between them more effectively in terms of the immunotherapeutic response. Finally, candidate compounds aimed at LUAD subtype differentiation were identified. This risk model based on the m 6 Abased lncRNAs may be promising for the clinical prediction of prognoses and immunotherapeutic responses in LUAD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

Huang

et al. 2021

Molecular Therapy - Nucleic Acids

165

141

View full text Add to dashboard Cite

show abstract

“…All these outcomes uncovered that G6PD A growing body of research manifested that quite a number of lncRNAs modulate protein-coding gene expression and involve in the crucial regulation processes of multiple types of human tumor, including in aerobic glycolysis (Liu et al 2019a, b;Shankaraiah et al 2018). For example, Xue et al elucidated that lncRNA ABHD11-AS1 facilitates the proliferation and aerobic glycolysis of non-small-cell lung cancer (Xue et al 2020). Wang et al demonstrated that lncRNA LINRIS was high-expressed in colorectal cancer tissues from patients with poor overall survival (OS), and stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer (Wang et al 2019a, b).…”

Section: Discussionmentioning

confidence: 99%

LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis

Deng

et al. 2021

Mol Med

View full text Add to dashboard Cite

Background Reprogrammed glucose metabolism of enhanced Warburg effect (or aerobic glycolysis) is considered as a hallmark of cancer. Long non-coding RNAs (lncRNAs) have been certified to play a crucial role in tumor progression. The current study aims to inquire into the potential regulatory mechanism of long intergenic non-protein coding RNA 242 (LINC00242) on aerobic glycolysis in gastric cancer. Method LINC00242, miR-1-3p and G6PD expression levels in gastric cancer tissues and cells were determined by qRT-PCR. Cell apoptosis or viability were examined by Flow cytometry or MTT assay. Western blot was utilized to investigate G6PD protein expression levels. Immunohistochemical (IHC) and hematoxylin and eosin (H&E) staining were used for histopathological detection. The targeted relationship between LINC00242 or G6PD and miR-1-3p was verified by luciferase reporter gene assay. Nude mouse xenograft was utilized to detect tumor formation in vivo. Result LINC00242 and G6PD was high-expressed in gastric cancer tissues and cells, and LINC00242 is positively correlated with G6PD. Silencing of LINC00242 or G6PD within gastric cancer cells prominently inhibited cell proliferation and aerobic glycolysis in vitro and relieved the tumorigenesis of gastric cancer in vivo. miR-1-3p was predicted to directly target both LINC00242 and G6PD. Overexpression of miR-1-3p suppressed gastric cancer cells proliferation and aerobic glycolysis. LINC00242 competitively combined miR-1-3p, therefore relieving miR-1-3p-mediated suppression on G6PD. Conclusion LINC00242 plays a stimulative role in gastric cancer aerobic glycolysis via regulation of miR-1-3p/ G6PD axis, therefore affecting gastric cancer cell proliferation.

show abstract

“…METTL3 can promote tumorigenesis and malignant progression, is highly expressed in a variety of malignant tumors, such as bladder cancer, breast cancer, and lung cancer, and is an indicator of poor patient prognosis [40][41][42]. It was found that the expression of METTL3-induced lncRNAs ABHD11-AS1 and LINC00958 was upregulated in non-small cell lung cancer (NSCLC) and liver cancer tissues and cells and closely associated with the poor prognosis of patients [43][44]. To investigate the biological characteristics of these m6A-related lncRNAs associated with prognosis, we classi ed, via consensus clustering, ccRCC patients into 2 subtypes based on the expression of lncRNAs.…”

Section: Discussionmentioning

confidence: 99%

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Qiu

Wang

Fan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Patients with advanced clear cell renal cell carcinoma (ccRCC) have a poor prognosis and lack effective prognostic biomarkers. This study uses bioinformatics analysis to identify N6-methyladenosine-related lncRNAs (m6A-related lncRNAs) as new prognostic biomarkers for ccRCC.Methods: Gene expression data and related clinical information of ccRCC patients were extracted from the Cancer Genome Atlas Database. m6A-related lncRNAs were obtained by co-expression analysis. Univariate Cox regression analysis was performed on these lncRNAs to find the prognostic-related m6A-related lncRNAs, and consensus clustering analysis was performed. The prognostic signature was screened by LASSO regression and a prognostic model was constructed. The predictive performance of the prognostic model was evaluated and validated by survival analysis and ROC curve analysis, etc. In addition, we also systematically analyzed the expression of immune checkpoints and immune cell infiltration in ccRCC patients.Results: First, 27 m6A-related lncRNAs associated with prognosis were identified, which were significantly differentially expressed between tumor and normal tissues. Consensus clustering analysis indicated that cluster 2 was associated with poor prognosis, low stromal score, high expression of PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, and immunosuppressive cell infiltration. The signaling pathways related to tumor progression, drug resistance, and angiogenesis and biological processes related to protein methylation and phosphatidic acid metabolism are significantly enriched in cluster 2. Subsequently, LASSO regression analysis was used to construct a prognostic risk model based on 7 m6A-related lncRNAs signature, which can be used as an independent prognostic indicator. After a series of analyses, it was shown that this model had good sensitivity and specificity, can predict the prognosis of patients with different clinical stratifications and was associated with the progression of ccRCC. The expression levels of immune checkpoints were significantly increased in high-risk patients, and there was a certain correlation between the risk score and immune cell infiltration. Conclusions: In summary, we constructed and validated a risk model that can independently predict the prognosis of ccRCC patients and reflect the immune microenvironment based on m6A-related lncRNAs; the model is conducive to the screening of biomarkers of ccRCC prognosis and may have the potential to reflect the response of ccRCCs to immunotherapy.

show abstract

m⁶A transferase METTL3‐induced lncRNA ABHD11‐AS1 promotes the Warburg effect of non‐small‐cell lung cancer

Cited by 133 publications

References 30 publications

m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Contact Info

Product

Resources

About

m6A transferase METTL3‐induced lncRNA ABHD11‐AS1 promotes the Warburg effect of non‐small‐cell lung cancer

Cited by 133 publications

References 30 publications

m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD

LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Contact Info

Product

Resources

About

m⁶A transferase METTL3‐induced lncRNA ABHD11‐AS1 promotes the Warburg effect of non‐small‐cell lung cancer